Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in ...

Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...

In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here. Patients with ...

With its latest acquisition, Lilly will carve out a spot in the PI3K inhibitors space in breast cancer, which for long was dominated by Novartis’ Piqray (alpelisib). In October 2024, Roche had a ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly has turned to a biotechnology startup for ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of ...

Figure 3: PtdIns(3,4,5)P 3 gradients are not required for chemotaxis. An exception is the PI3K-dependent chemotaxis of neutrophils towards attractants, such as interleukin-8 (IL-8). These cells ...

Sustained exposure to pathological stress stimulates the heart to hypertrophy, increasing disease and mortality risk. New therapies to blunt this process include targeting enzymes below the cell ...